Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as well as their implications for other applications like kidney disease and ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

In a powerful act of love and sacrifice, Julie Malliet donated her kidney to her husband, Dave, who had been battling chronic kidney disease for years.

For a Pleasant Hills couple, it's also the day one year ago, when they started a life-saving journey at Allegheny General ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Successful petitions to receive compassionate early release from federal prisons due to health issues are rare. They are even ...

Race may play a role in the waitlist experience, allograft quality and transplant outcomes of patients with autosomal ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

The future of healthcare is defined by this blend of technology and human expertise, offering new hope for a more efficient ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...